The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
Open accessAbstract
BACKGROUND: Xanthine oxidase inhibitors (XOI), classified as purine-like (allopurinol and oxypurinol) and non-purine (febuxostat and topiroxostat) XOI, present antioxidant properties by reducing the production of reactive oxygen species derived from purine metabolism. Oxidative stress is an important factor related to endothelial dysfunction and ischemia-reperfusion injury, and may be implicated in the pathogenesis of heart failure, hypertension, and ischemic heart disease. However, there is contradictory evidence regarding the possible cardiovascular (CV) protective effect exerted by XOI. Our objective is to compare the incidence of major adverse cardiovascular events (MACE), mortality, total (TCE) and specific CV events in randomized controlled trials (RCTs) testing XOI against placebo or no treatment. METHODS: PubMed, EMBASE, Web of Science, Cochrane Central, Lilacs databases were searched from inception to Dec 30 2016, along with hand searching. RCTs including exclusively adult individuals, lasting ≥ 4 weeks, with no language restriction, were eligible. Independent paired researchers selected studies and extracted data. Considering the expected rarity of events, Peto and DerSimonian/Laird odds ratios (OR), the latter in case of heterogeneity, were used for analysis. Random-effects meta-regression was used to explore heterogeneity. RESULTS: = 44%). Meta-regression associated increasing dose of allopurinol with higher risk of TCE and serious TCE (P < 0.05). Accordingly, lower doses (≤ 300 mg/day) of allopurinol reduced the risk of TCE, unlike higher doses. Non-purine-like XOI did not significantly reduce or increase the risk of adverse CV events, but confidence intervals were wide. Quality of evidence was generally low to moderate. CONCLUSIONS: Purine-like XOI may reduce the incidence of adverse CV outcomes. However, higher doses of allopurinol (> 300 mg/day) may be associated with loss of CV protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396 · cited 1×
“The articles were evaluated for risk of bias using the method described in the Cochrane handbook [25] by 2 independent reviewers.”
Higgins, J. P., Deeks, J. J., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch16 · Cited by 475
Impact of Oxypurinol in Patients With Symptomatic Heart Failure
Hare, J. M., Mangal, B., Brown, J., Fisher, C., Freudenberger, R., Colucci, W. S., Mann, D. L., Liu, P., Givertz, M. M., & Schwarz, R. P. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.068 · Cited by 392
Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis
Agarwal, V., Hans, N., & Messerli, F. H. (2013) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2012.00701.x · Cited by 173
Higgins, P., Dawson, J., Lees, K. R., McArthur, K., Quinn, T. J., & Walters, M. R. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00277.x · Cited by 164
Allopurinol and Cardiovascular Outcomes in Adults With Hypertension
MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06344 · Cited by 124
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Kenny, H. C., & Abel, E. D. (2019) · Circulation Research · doi:10.1161/circresaha.118.311371 · Cited by 660
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179221 · Cited by 595
RONS and Oxidative Stress: An Overview of Basic Concepts
Aranda-Rivera, A. K., Cruz-Gregorio, A., Arancibia-Hernández, Y. L., Hernández-Cruz, E. Y., & Pedraza-Chaverri, J. (2022) · Oxygen · doi:10.3390/oxygen2040030 · Cited by 384
Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis
Kimura, Y., Tsukui, D., & Kono, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212394 · Cited by 309
Metadata
- Authors
- Bredemeier, M., Lopes, L. M., Eisenreich, M. A., Hickmann, S., Bongiorno, G. K., d’Avila, R., Morsch, A. L. B., da Silva Stein, F., & Campos, G. G. D.
- Venue
- BMC Cardiovascular Disorders
- Published
- 2018-02-07
- Volume
- 18
- Issue
- 1
- Pages
- 24-24
- ISSN
- 1471-2261 (ISSN-L)
- OpenAlex
- W2787245380
- Cited by
- 188
- References
- 6
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1186/s12872-018-0757-9
- The paper
- Bredemeier, M., Lopes, L. M., Eisenreich, M. A., Hickmann, S., Bongiorno, G. K., d’Avila, R., Morsch, A. L. B., da Silva Stein, F., & Campos, G. G. D. (2018). Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-018-0757-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.